1,796 material Form 8-K filings that 1,448 companies we cover made with the SEC in May 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
CBRE Services, a wholly owned subsidiary of CBRE Group, completed a $750 million offering of 5.250% senior notes maturing June 1, 2036, guaranteed by the parent. The company said it intends to use the net proceeds to repay commercial paper borrowings, which shifts short-term debt into longer-term fixed-rate debt.
Principal amount: $750 million; issue date May 4, 2026; interest of 5.250% paid semi-annually
Notes mature June 1, 2036; first interest payment due December 1, 2026
Proceeds to repay borrowings under the company's commercial paper program
Indenture includes limits on liens, sale/leaseback transactions and mergers, and events of default including nonpayment
On May 4, 2026, Meta Platforms completed the sale of $25 billion in senior notes in six tranches maturing from 2031 to 2066. The filing shows the company is adding a large amount of long-term debt, which shareholders may watch for its effect on the company's borrowing costs and balance sheet.
Six tranches total $25 billion: $3 billion due 2031, $2 billion due 2033, $6 billion due 2036, $4 billion due 2046, $6 billion due 2056, and $4 billion due 2066.
Coupons range from 4.550% on the 2031 notes to 6.450% on the 2066 notes.
Citigroup Global Markets Inc. and Morgan Stanley & Co. LLC served as representatives of the underwriters under an agreement dated April 30, 2026.
The notes were issued under a fifth supplemental indenture to a base indenture with U.S. Bank Trust Company, National Association, as trustee.
West Enclave Merger Corp., a Cayman Islands blank check company listed on the NYSE, closed its initial public offering of 10,000,000 units on May 1, 2026, at $10.00 per unit for gross proceeds of $100,000,000. A simultaneous private placement of 425,000 units added $4,250,000, and $101,000,000 was placed in a trust account that holds the funds until a business combination is completed or shareholders redeem their shares.
IPO closed May 1, 2026: 10,000,000 units at $10.00 each, $100,000,000 gross proceeds; units trade on NYSE as "WENC U".
Private placement of 425,000 units to the sponsor and EarlyBirdCapital for $4,250,000, closed May 1, 2026.
$101,000,000 placed in trust; if no business combination within 21 months of the offering closing, public shares are redeemed unless shareholders approve an extension.
Board expanded to five members on April 29, 2026, with Jean-Michel Enriquez Dahlhaus and Hector Madero Rivero added; indemnity agreements signed with all directors and officers.
General Catalyst Global Resilience Merger Corp. closed its initial public offering on May 1, 2026, selling 40,250,000 GRAIL securities at $10.00 each, including the full exercise of the underwriters' over-allotment option, for gross proceeds of $402.5 million. The company is a blank check company with no business combination announced in the filing, and its proceeds are to be held in a trust account until it completes an initial business combination.
40,250,000 GRAIL securities sold at $10.00 each on May 1, 2026, for gross proceeds of $402.5 million, including 5,250,000 over-allotment securities
Sponsor GCGR Sponsor LLC bought 905,000 private placement GRAIL securities for $9.05 million
GRAIL securities began trading on Nasdaq as GCGRU on April 30, 2026; shares and warrants are expected to trade as GCGR and GCGRW once separated
Company must complete an initial business combination within 24 months of April 29, 2026, or 27 months if a letter of intent or agreement was signed within that period
Rein Therapeutics closed on May 4, 2026 the sale of 50,000,000 shares of common stock at $1.00 per share under an April 30 underwriting agreement with Konik Capital Partners, with net proceeds expected to be about $46.1 million. The company said the proceeds, with existing cash, are expected to fund operations into 2028 and its Phase 2 LTI-03 trial through completion. The offering adds shares outstanding and the filing also includes warrants to the underwriter and to Bios entities, which dilute existing shareholders.
50,000,000 shares sold at $1.00 per share before underwriting discounts; closed May 4, 2026
Expected net proceeds of about $46.1 million; underwriter has a 45-day option for up to 7,500,000 more shares
Underwriter warrants for up to 3% of shares sold, exercisable at $1.50 per share through April 30, 2031
Bios entities to receive warrants for 3,000,000 shares at $1.00 per share and defer conversion of 12,232 Series X preferred shares
Alcoa and its subsidiaries signed Amendment No. 3 to their revolving credit agreement with JPMorgan Chase Bank, N.A. as administrative agent. The amendment extends the facility's maturity to June 27, 2028 and removes certain credit spread and sustainability rate adjustments, while the total commitment stays at $1.25 billion. The filing describes this as an amendment of existing financing rather than new borrowing, and it does not report any drawn amount.
Revolving facility maturity extended to June 27, 2028
Aggregate commitments remain at $1.25 billion
Credit spread adjustment and sustainability rate adjustments removed
Participating lenders received a fee of 0.05% of their commitments
American Express issued $1.75 billion aggregate principal amount of 4.444% Fixed-to-Floating Rate Notes due May 3, 2030 on May 4, 2026, under an existing prospectus supplement dated April 27, 2026. The filing is administrative, covering the note issuance and related legal exhibits, and it does not report new financial results or changes to guidance.
Principal amount: $1,750,000,000 of 4.444% Fixed-to-Floating Rate Notes
Issuance date: May 4, 2026; maturity: May 3, 2030
Issued under a senior indenture with The Bank of New York Mellon as trustee, supplemented in 2021 and 2023
Filing includes a legal opinion from Benjamin L. Kuder, Esq. and an inline XBRL cover page
On April 30, 2026, Flex entered into a $1.45 billion senior delayed draw term loan credit facility with Citibank, N.A. as administrative agent. Flex said it will use the proceeds for general corporate purposes, including financing its acquisition of Electrical Power Products, Inc. (EP²), which it announced on May 4, 2026 had been completed. The facility adds borrowing capacity and debt covenants that shareholders should weigh against the company's leverage.
Credit facility totals $1.45 billion and matures 364 days after the first funding date of the term loans
Loans bear interest at Term SOFR or Base Rate plus a margin tied to Flex's senior unsecured debt ratings
Covenants require a Debt/EBITDA ratio of no more than 4.00 to 1.00 and an Interest Coverage Ratio of at least 3.00 to 1.00
EP² acquisition completion announced May 4, 2026; obligations are not guaranteed by any subsidiary at this time
CNS Pharmaceuticals agreed to sell 650,000 common shares and pre-funded warrants for 9,143,479 shares to institutional investors, with a closing expected May 5, 2026 and gross proceeds of approximately $22.5 million. The company plans to use the proceeds to acquire and advance new assets and for working capital, but the sale adds about 9.8 million shares that could dilute existing shareholders. The filing also reports a board resignation and the appointment of Michal Fisher as an independent director.
650,000 common shares sold at $2.30 per share; pre-funded warrants for 9,143,479 shares sold at $2.299 each
Expected closing on May 5, 2026; placement agent fee of 7.0% of gross proceeds
Company to file a resale registration statement within 15 days of closing and agreed to a 120-day limit on most new equity sales
Jerzy (George) Gumulka resigned from the Board; Michal Fisher appointed as an independent director
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.